ClinicalTrials.gg
CompletedNCT07105163OSTEOADUpdated Oct 6, 2026

Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis

An observational study in Post Menopausal Osteoporosis, sponsored by Procare Health Iberia S.L.. Completed at 20 sites in Spain. Open to female participants. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Procare Health Iberia S.L. · Observational

How we know

Updated Oct 6, 2026Now CompletedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
230
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Osteoporosis, Postmenopausal with a site in Spain — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · Spain.

Started
2025
with 1 other
Observational
Only one
of the 26
Registered
25th of 26
by date
Lead sponsor
1 of 26
Procare Health Iberia S.L.

Among the 26 studies in Osteoporosis, Postmenopausal with a site in Spain, this one is one of 2 that started in 2025, is the only observational one, and was the 25th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 26 studies in Osteoporosis, Postmenopausal with a site in Spain is open now. Recruiting first, the newest first:

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Osteoporosis, Postmenopausal with a site in Spain, or all of them as a file.
02

Study summary

This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis. The study will consist of a single visit that will coincide with one of the patient's usual follow-up visits according to standard clinical practice. During this visit, information will be collected from the patient's medical history and an interview will be conducted using 3 questionnaires to assess how and how often the patient takes the treatment, possible forgetfulness, and whether or not the patient is satisfied with their current treatment.

03

Conditions studied

  • Post Menopausal Osteoporosis

Keywords

  • Procare
  • Post menopausal osteoporosis
  • Bisphosphonate
  • calcium
  • vitamin D
  • supplement
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with postmenopausal osteoporosis who have been prescribed treatment with an oral bisphosphonate combined with Ca/D supplements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. - Women diagnosed with OP.
  2. - Women who had been prescribed oral treatment with a BP administered monthly or weekly together with a Ca/D supplement (sachets or chewable tablets) administered daily, at least 6 months prior to inclusion in the study.
  3. - Women who had given their written before participating in the study.

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
230 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Intergroup adherence

    To evaluate intergroup adherence to the most common oral regimens used in the treatment of postmenopausal OP that combine BP and Ca/D supplements, using a 8-items Morisky Medication Adherence Scale

    Time frame: Day 1

Secondary outcomes

  1. Persistence intergroup

    To evaluate, intergroup, the persistence to the most common oral regimens used in the treatment of postmenopausal OP that combine BP and Ca/D supplements. It will be evaluated over time from the start of the combination of both until the first end date of administration of either one, and by the percentage of patients who continue with the combined treatment since its prescription

    Time frame: Day 1

  2. Adherence intragroup

    To evaluate, intragroup, the adherence to the prescribed usual oral regimens, using a 8-items Morisky Medication Adherence Scale

    Time frame: Day 1

  3. Persistence intragroup

    To evaluate, intragroup, the persistence to the prescribed usual oral regimens.

    Time frame: Day 1

  4. Factors of non-adherence

    To evaluate possible determining factors of non-adherence to the prescribed usual oral regimens and their comparison between the different regimens.

    Time frame: Day 1

  5. Factors of non-persistence

    To evaluate possible determining factors of non-persistence to the prescribed usual oral regimens and their comparison between different regimens.

    Time frame: Day 1

  6. Treatment satisfaction

    To evaluate the patient's satisfaction with the combined treatment received using a Likert scale.

    Time frame: Day 1

07

Study locations

20 sites
  • Clinica Gaias Santiago
    Santiago de Compostela, A coruña, Spain
  • CP Dr Caracuel
    Córdoba, Andalusia, Spain
  • Hospital Reina Sofia
    Córdoba, Andalusia, Spain
  • Hospital Virgen del Rocio
    Seville, Andalusia, Spain
  • CP Dr Agramonte
    Palma de Mallorca, Balearic Islands, Spain
  • CP Dr Balta
    Palma de Mallorca, Balearic Islands, Spain
  • CHU Insular - H Materno-Infantil
    Las Palmas de Gran Canaria, Canary Islands, Spain
  • Hospital Zamora
    Zamora, Castille and León, Spain
  • Clinica Sagrada Familia
    Barcelona, Catalonia, Spain
  • CP Dra Sanchez
    Barcelona, Catalonia, Spain
  • Hospital del Mar
    Barcelona, Catalonia, Spain
  • Hospital del Tajo
    Aranjuez, Madrid, Spain
  • CP Dr Solano
    Madrid, Madrid, Spain
  • CP Dr Zafra
    Madrid, Madrid, Spain
  • CP Dra Gerechter
    Madrid, Madrid, Spain
  • Hospital Infanta Leonor
    Madrid, Madrid, Spain
  • Hospital Virgen del Mar
    Madrid, Madrid, Spain
  • CP Dr Larrauri
    Vigo, Pontevedra, Spain
  • CP Dra Medrano
    Alicante, Valencia, Spain
  • CP Dra Tejon
    Alicante, Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Dec 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Aug 5, 2025
StartActual
Mar 3, 2025
Primary completionActual
Dec 3, 2025
CompletionActual
Dec 3, 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 6, 2026
Sites
1 site removed
Show 1 removed
  • CHU Insular - H Materno-Infantil · Las Palmas de Gran Canaria, Spain
Oct 6, 2026
Enrollment
480 (estimated)→230 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • CHU Insular - H Materno-Infantil · Las Palmas de Gran Canaria, Spain
    Enrollment 480 (estimated)→230 (actual)
    + 4 other changes: verification date, date precision, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07105163
Lead sponsor
Procare Health Iberia S.L.
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Mar 3, 2025
Primary completion
Dec 3, 2025
Completion
Dec 3, 2025
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion